Michael J. Farrell sold $3.6M of RMD
Chief Executive Officer at RESMED INC. 14,683 shares at an average of $246.26, traded Nov 7, 2024, filed Nov 12, 2024.
Score components
- +25RoleCEO
- +25Trade size$3.6M at market
- 0Share of holdings soldSold 3.1% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.9%, 3m -4.0%, 6m +0.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-24-027086, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2024 | MOption exercise ResMed Common Stock10b5-1 | +14,683 | $84.98 | $1.2M | 478,937 | Nov 12, 2024 |
| Nov 7, 2024 | SOpen-market sale ResMed Common Stock10b5-1 | -14,683 | $246.26 | $3.6M | 464,254 | Nov 12, 2024 |
| Nov 11, 2024 | FTax withholding ResMed Common Stock10b5-1 | -3,101 | $252.38 | $783k | 461,152 | Nov 12, 2024 |
| Nov 11, 2024 | FTax withholding ResMed Common Stock10b5-1 | -2,227 | $252.38 | $562k | 458,925 | Nov 12, 2024 |
| Nov 11, 2024 | FTax withholding ResMed Common Stock10b5-1 | -3,453 | $252.38 | $871k | 455,472 | Nov 12, 2024 |
| Nov 7, 2024 | MOption exercise ResMed Common Stock Optionsderivative10b5-1 | -14,683 | $0.00 | $0 | 0 | Nov 12, 2024 |
Related signals
Other insiders at RESMED INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | RESMED INC | Michael J. Farrell Chairman and CEO | $1.1M 4,991 shares | -1% | |
| 23Weak | RESMED INC | Michael J. Farrell Chairman and CEO | $1.1M 4,991 shares | -1% | |
| 16Weak | RESMED INC | Peter C Farrell director | $228k 970 shares | -2% | |
| 8Weak | RESMED INC | Peter C Farrell director | $241k 945 shares | -1% | |
| 30Weak | RESMED INC | Michael J. Farrell Chief Executive Officer | $2.0M 8,009 shares | -2% | |
| 28Weak | RESMED INC | Peter C Farrell director | $495k 2,000 shares | -3% | |
| 30Weak | RESMED INC | Brett Sandercock Chief Financial Officer | $244k 1,000 shares | -1% | |
| 10Weak | RESMED INC | Michael J Rider Global General Counsel | $9,995 41 shares | -0% | |
| 40Moderate | RESMED INC | Brett Sandercock Chief Financial Officer | $891k 3,644 shares | -4% | |
| 38Weak | RESMED INC | Jan De Witte director | $487k 2,000 shares | -26% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.